Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study
Jennifer E. Nyland, Nazia Raja‐Khan, Kerstin Bettermann, et al.
Diabetes (2021) Vol. 70, Iss. 12, pp. 2903-2916
Open Access | Times Cited: 63

Showing 26-50 of 63 citing articles:

Effect of 2 vs 3 Doses of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease: A Population-based Propensity Matched Analysis
Aakash Desai, Parakkal Deepak, Raymond K. Cross, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 10, pp. 1563-1571
Open Access | Times Cited: 11
Single-cell RNA sequencing analysis of lung cells in COVID-19 patients with diabetes, hypertension, and comorbid diabetes-hypertension
Xin Zhang, Xiaoqian Deng, Liangliang Zhang, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 6
Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
Djordje S. Popovic, Νικόλαος Παπάνας, Anca Pantea Stoian, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 12, pp. 3037-3054
Open Access | Times Cited: 15
Hospitalization and mortality in patients with COVID-19 with or at risk of type 2 diabetes: data from five health systems in Pennsylvania and Maryland
Hsin‐Chieh Yeh, Jennifer L. Kraschnewski, Lan Kong, et al.
BMJ Open Diabetes Research & Care (2022) Vol. 10, Iss. 3, pp. e002774-e002774
Open Access | Times Cited: 10
Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations
Thiago Bosco Mendes, Alexandre Barbosa Câmara de Souza, Bruno Halpern
Diabetology & Metabolic Syndrome (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Trends in All-Cause and Cause-Specific Mortality Among Individuals With Diabetes Before and During the COVID-19 Pandemic in the U.S.
Donghee Kim, Omar Alshuwaykh, Keeryth K. Sandhu, et al.
Diabetes Care (2022) Vol. 45, Iss. 6, pp. e107-e109
Open Access | Times Cited: 9
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis
Kegang Zhan, Liuqi Weng, Qi Li, et al.
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 7, pp. 776-786
Open Access | Times Cited: 9
Association of Premorbid GLP-1RA and SGLT-2i Prescription Alone and in Combination with COVID-19 Severity
Klara R. Klein, Trine J. Abrahamsen, Anna R. Kahkoska, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1169-1186
Open Access | Times Cited: 1
Identification of common genes and pathways between type 2 diabetes and COVID-19
Ya Wang, Kai Li, Shuangyang Mo, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 1
Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial
Khaled Baagar, Thamer Alessa, Mohamed Abu‐Farha, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension
Jong Han Lee
Medical Hypotheses (2021) Vol. 158, pp. 110739-110739
Open Access | Times Cited: 12
Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern
Christian Setz, Maximilian Große, Janina Auth, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6830-6830
Open Access | Times Cited: 8
Antidiabetic Drug Efficacy in Reduction of Mortality during the COVID-19 Pandemic
Daniel Gonikman, Dmitrijs Kustovs
Medicina (2023) Vol. 59, Iss. 10, pp. 1810-1810
Open Access | Times Cited: 4
Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis
Jean‐Etienne Poirrier, Juliana Meyers, Saurabh Nagar, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2585-2593
Open Access | Times Cited: 7
Challenges in hyperglycemia management in critically ill patients with COVID-19
Rajesh Kethireddy, Darshan Gandhi, Asim Kichloo, et al.
World Journal of Critical Care Medicine (2022) Vol. 11, Iss. 4, pp. 219-227
Open Access | Times Cited: 5
Chronic Pancreatitis and Risk of Atherosclerotic Cardiovascular Disease
Aakash Desai, Saurabh Chandan, Daryl Ramai, et al.
Pancreas (2023) Vol. 52, Iss. 1, pp. e21-e28
Closed Access | Times Cited: 2
Effects of novel glucose-lowering drugs on the COVID-19 patients with diabetes: A network meta-analysis of clinical outcomes
Yang Yang, Ling Zhao, Yeying Wang, et al.
International Journal of Diabetes in Developing Countries (2023) Vol. 44, Iss. 3, pp. 426-436
Open Access | Times Cited: 2
The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
Health Science Reports (2023) Vol. 6, Iss. 9
Open Access | Times Cited: 2
Relationship between Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Disease in Chronic Respiratory Disease and Diabetes
Jun‐Jun Yeh, Chih-Chien Li, Chang-Wen Tan, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 488-488
Open Access
Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis
Limin Zhao, Xiehui Chen, Mei Qiu
Frontiers in Endocrinology (2022) Vol. 12
Open Access | Times Cited: 3
Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care—APHOSDIAB—COVID-19 Multicenter Study
Domingo Orozco‐Beltrán, Juan Francisco Merino-Torres, Antonio Pérez, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2092-2092
Open Access | Times Cited: 3
Current management of diabetes patients with COVID-19
Arup Kumar Misra, Gaurav Rangari, C Madhavrao, et al.
Expert Review of Endocrinology & Metabolism (2023) Vol. 18, Iss. 2, pp. 199-207
Closed Access | Times Cited: 1
Association of COVID-19 outcomes with diabetes in the Veneto region (north-east italy): Epidemiological insights for the endemic phase?
Francesco Piarulli, Massimo Carollo, Eugenio Ragazzi, et al.
Nutrition Metabolism and Cardiovascular Diseases (2023) Vol. 33, Iss. 11, pp. 2141-2150
Open Access | Times Cited: 1
COVID-19, Obesity, and GRP78: Unraveling the Pathological Link
Jihoon Shin, Iichiro Shimomura
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 3, pp. 183-196
Open Access | Times Cited: 1
Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
Т. Н. Маркова, М. А. Лысенко, M. Stas, et al.
Diabetes Mellitus (2023) Vol. 26, Iss. 6, pp. 537-548
Open Access | Times Cited: 1

Scroll to top